Tyra Biosciences (NASDAQ:TYRA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02, Zacks reports.
Tyra Biosciences Stock Performance
TYRA traded up $0.02 during midday trading on Friday, reaching $10.09. 394,066 shares of the company were exchanged, compared to its average volume of 259,260. The company has a market cap of $535.68 million, a price-to-earnings ratio of -6.27 and a beta of 1.17. Tyra Biosciences has a one year low of $6.42 and a one year high of $29.60. The company's fifty day moving average price is $9.64 and its 200 day moving average price is $13.31.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Monday, March 31st. Wedbush reissued an "outperform" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences has a consensus rating of "Buy" and a consensus price target of $30.83.
Check Out Our Latest Stock Analysis on Tyra Biosciences
Tyra Biosciences Company Profile
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
